US · Healthcare · Biotechnology
EPS came in at -1.10 against a street estimate of -1.21 — a beat of 9.1%.
Analysts rate Viking Therapeutics Inc a strong buy (18 buy, 2 hold, 0 sell out of 20) with an average price target of $94.71.
CONFIDENT Viking advanced VK2735 (dual GLP-1/GIP agonist) Phase III trials on track with full enrollment; launched oral formulation Phase III in Q4; initiated VK3019 amylin agonist Phase I; maintained $502M cash; no revenue yet. Q2 2026 No geographic segments discussed on call. Analysts pressed design specifics (oral size, maintenance breakouts, AE reporting) and VK3019 strategy. Management acknowledged maintenance trial is not designed for early safety signals (known tolerability risk is front-loaded), confirmed oral Phase III is smaller, and noted amylin combo requires 2027+ timeline and Phase I/II safety data. 2026-07-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 4.98% |
| BlackRock Inc | 4.87% |
| State Street Corp | 4.41% |
| Vanguard Capital Management, LLC | 3.97% |
| Vanguard Portfolio Management, LLC | 3.53% |
| Two Sigma Investments LLC | 3.10% |
| Morgan Stanley - Brokerage Accounts | 2.37% |
| Geode Capital Management, LLC | 1.65% |
| Document | Date |
|---|---|
| Material agreement · Q3 2026 HEADLINE NUMBERS • Viking Therapeutics raised approximately $547.8 million in net proceeds through simultaneous stock and convertible-debt offerings, | 2026-09-28 |
| Company announcement · Q3 2026 VIKING THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company announced top-line results from a maintenance study of VK2735 on September 22, 20 | 2026-09-22 |
| Quarterly report · Q2 2026 VIKING THERAPEUTICS, INC. — 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash and short-term investments combined: $501.7 million as of June 30, 2026 ( | 2026-07-29 |
| Results announced · Q3 2026 VIKING THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash position: $502 million in cash, cash equivalents, and short-term investments a | 2026-07-29 |
| Shareholder vote results · Q2 2026 VIKING THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 19, 2026 • 115,893,943 total shares outstanding as of March 20, 2 | 2026-05-26 |
| Quarterly report · Q1 2026 VIKING THERAPEUTICS, INC. — 10-Q SUMMARY (Q1 2026) HEADLINE NUMBERS • Cash and short-term investments combined: $602.964 million (March 31, 2026), d | 2026-04-30 |
| Results announced · Q2 2026 VIKING THERAPEUTICS Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $603 million in cash, cash equivalents and short-term invest | 2026-04-29 |
| Proxy statement · Q2 2026 VIKING THERAPEUTICS, INC. — 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1 — Election of Directors: Elect two Class II di | 2026-04-01 |
Readable in the app.
| Announcement | Date |
|---|---|
| Phase 3 obesity trial enrollment complete; oral formulation advancing to Phase 3 Viking Therapeutics, a clinical-stage biotech company, announced strong progress on its obesity drug pipeline. The company's lead candidate VK2735—a dual GLP-1/GIP receptor agonist—completed | 2026-02-11 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Viking Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.